Literature DB >> 10846077

Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo.

W P Halford1, P A Schaffer.   

Abstract

The reduced efficiency with which herpes simplex virus type 1 (HSV-1) mutants establish latent infections in vivo has been a fundamental obstacle in efforts to determine the roles of individual viral genes in HSV-1 reactivation. For example, in the absence of the "nonessential" viral immediate-early protein, ICP0, HSV-1 is severely impaired in its ability to (i) replicate at the site of inoculation and (ii) establish latency in neurons of the peripheral nervous system. The mouse ocular model of HSV latency was used in the present study to determine if the conditions of infection can be manipulated such that replication-impaired, ICP0-null mutants establish wild-type levels of latency, as measured by viral genome loads in latently infected trigeminal ganglia (TG). To this end, the effects of inoculum size and transient immunosuppression on the levels of acute replication in mouse eyes and of viral DNA in latently infected TG were examined. Following inoculation of mice with 2 x 10(3), 2 x 10(4), 2 x 10(5), or 2 x 10(6) PFU/eye, wild-type virus replicated in mouse eyes and established latency in TG with similar efficiencies at all four doses. In contrast, increasing the inoculum size of the ICP0-null mutants n212 and 7134 from 2 x 10(5) to 2 x 10(6) PFU/eye significantly decreased the levels of infectious virus detected in the tear films of mice from days 4 to 9 postinfection. In an attempt to establish the biological basis for this finding, the effect of viral dose on the induction of the host proinflammatory response was examined. Quantitative reverse transcription-PCR demonstrated that increasing the inoculum of 7134 from 2 x 10(4) to 2 x 10(6) PFU/eye significantly increased the expression of proinflammatory (interleukin 6), cell adhesion (intercellular adhesion molecule 1), and phagocyte-associated (CD11b) genes in mouse eyes 24 h postinfection. Furthermore, transient immunosuppression of mice with cyclophosphamide, but not cyclosporin A, significantly enhanced both the levels of acute n212 and 7134 replication in the eye and the levels of mutant viral genomes present in latently infected TG in a dose-dependent manner. Thus, the results of this study demonstrate that acute replication in the eye and the number of ICP0-null mutant genomes in latently infected TG can be increased to wild-type levels for both n212 and 7134 by (i) optimization of inoculum size and (ii) transient immunosuppression with cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846077      PMCID: PMC112092          DOI: 10.1128/jvi.74.13.5957-5967.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  RELATIONSHIP BETWEEN THE ENVELOPE AND THE INFECTIVITY OF HERPES SIMPLEX VIRUS.

Authors:  K O SMITH
Journal:  Proc Soc Exp Biol Med       Date:  1964-03

2.  Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency.

Authors:  D A Leib; D M Coen; C L Bogard; K A Hicks; D R Yager; D M Knipe; K L Tyler; P A Schaffer
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Herpes simplex virus genes involved in latency in vitro.

Authors:  J Russell; N D Stow; E C Stow; C M Preston
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

4.  Herpes simplex virus ICP0 mutants are hypersensitive to interferon.

Authors:  K L Mossman; H A Saffran; J R Smiley
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

6.  The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide.

Authors:  M C Berenbaum; W A Cope; J A Double
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

7.  Effects of cyclophosphamide on lymphoid tissues labelled with 5-iodo-2-deoxyuridine- 125 I and 51 Cr.

Authors:  J L Turk; L W Poulter
Journal:  Int Arch Allergy Appl Immunol       Date:  1972

8.  The recovery of immune responsiveness after treatment with cyclophosphamide.

Authors:  J Marbrook; B C Baguley
Journal:  Int Arch Allergy Appl Immunol       Date:  1971

9.  A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency.

Authors:  D A Leib; C L Bogard; M Kosz-Vnenchak; K A Hicks; D M Coen; D M Knipe; P A Schaffer
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

10.  Repression and activation of the genome of herpes simplex viruses in human cells.

Authors:  B L Wigdahl; H C Isom; F Rapp
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

View more
  39 in total

1.  Herpes simplex virus 1 ICP0 phosphorylation site mutants are attenuated for viral replication and impaired for explant-induced reactivation.

Authors:  Heba H Mostafa; Thornton W Thompson; Anna S Kushnir; Steve D Haenchen; Adam M Bayless; Joshua G Hilliard; Malen A Link; Lisa A Pitcher; Emma Loveday; Priscilla A Schaffer; David J Davido
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment.

Authors:  Shih-Heng Chen; Angela Pearson; Donald M Coen; Shun-Hua Chen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 3.  Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1.

Authors:  Ryan Hagglund; Bernard Roizman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Development of a novel ex vivo model of corneal fungal adherence.

Authors:  Qingjun Zhou; Hao Chen; Mingli Qu; Qian Wang; Lingling Yang; Lixin Xie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-12-24       Impact factor: 3.117

5.  Early establishment of gamma-herpesvirus latency: implications for immune control.

Authors:  Emilio Flaño; Qingmei Jia; John Moore; David L Woodland; Ren Sun; Marcia A Blackman
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

6.  ICP22 is required for wild-type composition and infectivity of herpes simplex virus type 1 virions.

Authors:  Joseph S Orlando; John W Balliet; Anna S Kushnir; Todd L Astor; Magdalena Kosz-Vnenchak; Stephen A Rice; David M Knipe; Priscilla A Schaffer
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Phosphorylation site mutations affect herpes simplex virus type 1 ICP0 function.

Authors:  David J Davido; William F von Zagorski; William S Lane; Priscilla A Schaffer
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Construction and characterization of a herpes simplex virus type I recombinant expressing green fluorescent protein: acute phase replication and reactivation in mice.

Authors:  John W Balliet; Anna S Kushnir; Priscilla A Schaffer
Journal:  Virology       Date:  2007-01-17       Impact factor: 3.616

9.  Re-evaluating natural resistance to herpes simplex virus type 1.

Authors:  William P Halford; John W Balliet; Bryan M Gebhardt
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  ICP0 is not required for efficient stress-induced reactivation of herpes simplex virus type 1 from cultured quiescently infected neuronal cells.

Authors:  Craig S Miller; Robert J Danaher; Robert J Jacob
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.